Clotinab, exclusive in the bio-anti-hemolysis market

Abciximab's first biosimilar

Lilly's original Reopro withdrew from the domestic market in 2017

Low Drug Market Penetration Advantage

In the anti-hemorrhagic biopharmaceutical market, Korean biosimilar Clotinab is dominating the market.

 

According to data on drug distribution performance, ISU ABXIS Clotinab's 2021 performance was 2.8 billion won, dominating the Abciximab biosimilar market.

 

The sales of the product in 2018, 2019, and 2020 are 3,048 million won, 2,920 million won, and 2.94 billion won, and the cumulative performance of 3Q in 2022 is about 1,88 billion won.

 

Clotinab's dominance is attributed to the withdrawal of the original biopharmaceutical Lilly Reopro from the market.

 

Clotinab, the first antibody biosimilar title in Korea, challenged Reopro, which boasts 400 billion won in global sales in 2007.

 

In the early days of its launch, it recorded around 400 million won in performance, but gradually expanded its scope by passing the so-called "Big 5" hospitals DC such as Seoul National University Hospital, Asan Hospital, Severance Hospital, St.

 

Mary's Hospital, and Samsung Seoul Hospital.

 

It is understood that the decisive cause of crossing the barrier to entry into the original drug lies in securing drug equivalence with relatively low drug prices.

 

The drug price of Clotinab 2.5ml·5ml is listed at 315,084 won and 378,102 won, while Reopro's insurance price was 472,627 won, about 100,000 won higher.

 

Reopro was completely withdrawn from the domestic market in 2017, with the appearance of around 10 million won.

 

This drug is used as an auxiliary treatment for Heparin and Aspirin to prevent ischemic heart complications in high-risk patients during PTCA procedures.

 

As a medication guide be careful of antithrombotic drugs, bleeding can be suspected if symptoms such as brown urine, dizziness, and headache appear during administration.

 

In addition, patients who are about to undergo procedures and surgeries that are expected to bleed should stop administering drugs for a certain period of time because they may have difficulty stopping bleeding.